Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The term "peptide" describes a broad category of molecules made from amino acids, while GLP-1 represents one specific peptide hormone with proven effects on weight management. Understanding this distinction helps patients make informed choices about which therapies align with their metabolic needs. PlexusDx specializes in precision GLP-1 and dual-peptide protocols delivered through licensed 503A compounding pharmacies.

What Is GLP-1 and How Does It Differ From Other Peptides?

GLP-1, or glucagon-like peptide-1, is a naturally occurring peptide hormone produced by intestinal cells in response to nutrient intake. Your body uses GLP-1 to slow stomach emptying, increase feelings of fullness, and regulate blood glucose levels after meals. While peptides as a category include thousands of different molecular structures, GLP-1 belongs to the incretin hormone family and has a distinct mechanism separate from other peptide pathways.

Many peptides exist throughout your body—growth hormone-releasing peptides, natriuretic peptides, and neuropeptides among them—but each triggers different cellular responses. GLP-1 works specifically on receptors found in the brain, pancreas, and gastrointestinal system to coordinate appetite suppression and metabolic regulation. This targeted action is why GLP-1 therapies have become central to weight management protocols, whereas other peptides address different physiological functions.

How GLP-1 Medications Support Weight Loss at the Cellular Level

GLP-1 receptor agonists like semaglutide bind to GLP-1 receptors in the hypothalamus, the brain region controlling hunger signals and energy expenditure. This binding reduces appetite intensity and increases satiety, allowing patients to consume fewer calories without constant hunger. Clinical trials have demonstrated sustained weight reduction when GLP-1 therapy is combined with lifestyle modifications.

Beyond appetite control, GLP-1 activation improves insulin secretion in response to meals, which helps stabilize blood glucose fluctuations that often drive cravings and energy crashes. The dual action—appetite suppression plus metabolic stabilization—creates a biochemical environment favoring gradual, sustainable weight loss. PlexusDx Semaglutide Injection starts at $149 per month and delivers consistent GLP-1 receptor activation across all commitment tiers without flat per-compound pricing increases.

Peptide Pathways and Genetic Variations in Weight Management

Your genetic makeup influences how effectively you respond to GLP-1 therapy and whether additional peptide pathways require activation. Key genetic variants—including GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609—determine your individual peptide sensitivity and metabolic capacity. Individuals with certain variant profiles may benefit from dual-peptide approaches that activate both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) pathways.

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month) to map 14 metabolic pathways and 150+ genetic insights related to peptide responsiveness. This testing identifies whether single-peptide protocols like Semaglutide Injection align with your biology, or whether dual-compound options like GLP-Squared Injection (combining semaglutide and tirzepatide) better address your genetic predispositions. Genetic guidance personalizes therapy selection and increases the likelihood of meaningful weight loss outcomes.

Semaglutide Injection vs. Oral Peptide Therapies: Which Is Right for You?

Semaglutide Injection delivers GLP-1 receptor activation through subcutaneous weekly dosing, achieving consistent peptide levels and reliable appetite suppression. The injectable route bypasses first-pass hepatic metabolism, allowing lower doses to achieve therapeutic effect compared to oral formulations. PlexusDx Semaglutide Injection starts at $149 per month through licensed 503A compounding pharmacies serving all 50 states without insurance requirements.

Oral Semaglutide offers convenience for patients preferring daily dosing without needles, though absorption variability requires higher doses and may affect cost-effectiveness. PlexusDx Oral Semaglutide starts at $249 per month and maintains flat monthly pricing regardless of dose escalation. Your choice between injection and oral depends on lifestyle preference, absorption tolerance, and whether your genetic profile suggests need for dual-peptide activation; PlexusDx specialists can review your Precision Peptide test results to guide this decision.

Understanding the Compounding Advantage for Personalized GLP-1 Therapy

Compounded GLP-1 medications from licensed 503A pharmacies allow dose customization and rapid formulation adjustments that mass-manufactured FDA-approved drugs cannot match. PlexusDx partners exclusively with 503A compounding facilities—not 503B manufacturers—ensuring each medication is prepared under pharmacist oversight for individual patient protocols. This personalization extends to combination therapies: patients whose genetic testing indicates suboptimal single-peptide response can access GLP-Squared Injection, blending semaglutide and tirzepatide in one formulation.

The compounding model eliminates rigid dose ladders typical of branded medications, meaning your dose may increase during treatment while your price remains flat at $149 per month for Semaglutide Injection or $249 per month for Tirzepatide Injection. HSA and FSA funds cover all PlexusDx compounded peptides, improving affordability and compliance. No membership fees or insurance requirements apply, making precision GLP-1 therapy accessible to patients nationwide.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is GLP-1 considered a peptide, and are all peptides GLP-1?

Yes, GLP-1 is a peptide hormone, but not all peptides are GLP-1. Peptides are short chains of amino acids found throughout your body serving different functions. GLP-1 specifically regulates appetite and blood glucose, while other peptides control growth, immune response, or hormone signaling. PlexusDx focuses on GLP-1 and dual-peptide therapies proven for weight management.

How much weight can I expect to lose with GLP-1 therapy from PlexusDx?

Clinical trials show GLP-1 receptor agonists produce average weight reductions of 5–15% of body weight over 12–16 weeks when combined with lifestyle changes. Individual outcomes vary based on genetic predisposition, adherence, and metabolic factors. PlexusDx Precision Peptide Genetic Testing identifies your peptide-pathway response profile, helping predict realistic weight loss timelines and optimal therapy selection.

Why does PlexusDx pricing stay flat regardless of dose increases?

PlexusDx uses compounded formulations prepared by licensed 503A pharmacies, allowing flexible dosing without manufacturing constraints that drive flat per-compound pricing in mass-produced medications. Your dose may increase during treatment as tolerance develops, but your monthly commitment price—starting at $149/mo for Semaglutide Injection—remains constant across all tiers. This model removes cost barriers to safe dose optimization.

What side effects should I expect from GLP-1 therapy?

Common side effects include nausea, constipation, and mild gastrointestinal discomfort during the first 2–4 weeks as your body adjusts to decreased appetite and altered digestion. Most side effects resolve with time and dose titration. Serious side effects are rare but may include pancreatitis or thyroid concerns in vulnerable populations. PlexusDx recommends baseline health screening and ongoing provider communication to monitor tolerance.

How does the Precision Peptide Genetic Test help me choose the right GLP-1 therapy?

The Precision Peptide Genetic Test ($99 add-on after first month) analyzes variants in GLP1R, GIPR, MC4R, and FTO genes across 14 metabolic pathways. Results reveal whether your biology favors single-peptide GLP-1 therapy (Semaglutide Injection at $149/mo) or dual-peptide activation (GLP-Squared Injection at $249/mo). This genetic guidance personalizes your protocol and improves treatment success rates.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves